Solving COVID: April 14, 2021

Antibody cocktails show promise, Pfizer seeks authorization for vaccine for adolescents, and more

A vaccination.
(Image credit: Illustrated | Getty Images, iStock)

1. Where things stand

While India, parts of South America, and other areas of the world are experiencing another wave of COVID-19, the U.S. appears to be treading water with new cases and continuing a downward trend in deaths. According to The Washington Post's tracker, the seven-day average of COVID-19 deaths was 765 on Tuesday, a slight uptick from the weekend but a rate last seen Oct. 20. A running count by economist Patrick Chovanec put Tuesday's seven-day average at 748, the lowest rate since Oct. 17. While deaths have declined 2 percent in the past week, hospitalizations rose 2.6 percent and new cases were up 11 percent, the Post reports. Some parts of the U.S., notably Michigan, are faring much worse, with per capita cases up 18 percent to a new high and deaths rising 32 percent. Overall, 563,449 Americans have died from COVID-19, according to Johns Hopkins University. And 122.3 million Americans have received at least one dose of a COVID-19 vaccine, including 75.3 million people — or 23 percent of the U.S. population — fully vaccinated.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us